期刊
EMERGING INFECTIOUS DISEASES
卷 23, 期 8, 页码 1419-1421出版社
CENTERS DISEASE CONTROL
DOI: 10.3201/eid2308.170162
关键词
-
资金
- Fundacao para a Ciencia e a Tecnologia (FCT) through CESAM [UID/AMB/50017/2013]
- ESF (EU)
- POPH funds (Programa Investigador FCT) [IF/00492/2013]
- FCT [SFRH/BPD/81509/2011, SFRH/BPD/114855/2016]
- Fundação para a Ciência e a Tecnologia [SFRH/BPD/114855/2016, SFRH/BPD/81509/2011] Funding Source: FCT
Escherichia coli Ec36 was recovered from a patient in Portugal after treatment with meropenem and colistin. Besides an IncF plasmid with Tn1441d-blaKPC-3, already reported in clinical strains in this country, E. coli Ec36 co-harbored an IncX4:: mcr-1 gene. Results highlight emerging co-resistance to carbapenems and polymyxins after therapy with drugs from both classes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据